登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688607 证券简称：康众医疗 公告编号：2026-008 江苏康众数字医疗科技股份有限公司关于向激励对象首次授予股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●首次授予日：2026年2月12日 ●首次授予数量：400.00万份 ●激励方式：股票期权 江苏康众数字医疗科技股份有限公司（以下简称"公司"）于2026年2月12日召开第三届董事会第十六次 （临时）会议，审议通过《关于向激励对象首次授予股票期权的议案》，根据《上市公司股权激励管理 办法》《上海证券交易所科创板股票上市规则》《科创板上市公司自律监管指南第4号—股权激励信息 披露》《2026年股票期权激励计划（草案）》等有关规定，公司董事会认为2026年股票期权激励计划 （以下简称"本激励计划"）的授予条件已经成就，根据公司2026年第一次临时股东会的授权，公司董事 会同意确定2026年2月12日作为首次授予日，向符合资格的50名激励对象授予400.00万份股票期权，行 权 ...

Group 1 - Shenzhen has reached a milestone with over 600 listed companies, including 426 domestic and 174 overseas, with a total market capitalization exceeding 19 trillion yuan as of January 2026 [1] - The history of Shenzhen's listed companies reflects the evolution of China's modern corporate system, starting from the first stock issued in Bao'an in 1983 [2] - The establishment of the SME Board in 2004 and the Growth Enterprise Market in 2009 opened capital channels for private technology enterprises, with Shenzhen companies occupying significant positions [3] Group 2 - Recent years have seen a new wave of companies redefining "Shenzhen speed," with notable listings such as Yuntian Lifei and Youbixuan, showcasing rapid growth and innovation [4] - New companies listed on the Science and Technology Innovation Board and the Growth Enterprise Market indicate Shenzhen's proactive embrace of capital market reforms and alignment with cutting-edge technology [5] - In the first three quarters of 2025, Shenzhen-listed companies achieved a total revenue of 5.20 trillion yuan and a net profit of 457.8 billion yuan, reflecting strong growth in the manufacturing sector [7] Group 3 - The Hong Kong market has seen significant activity, with 27 new companies raising a total of 29.57 billion HKD, and over 70% of these companies experiencing stock price increases on their first trading day [7] - The strong performance of companies like BYD, which raised over 43.5 billion HKD in a single refinancing, highlights the robust capital market environment in Shenzhen [7] - Shenzhen's high-tech exports, including drones and 3D printers, grew by 10.1% in 2025, supported by a solid foundation of national high-tech enterprises [7] Group 4 - The journey from the first stock in 1983 to 600 listed companies today illustrates Shenzhen's transformation from a pilot city to a benchmark for capital markets in China [8] - Each listed company represents a milestone for Shenzhen, indicating that reaching 600 is not an endpoint but a new starting point for further growth [8]

Group 1 - Shenzhen's listed companies are experiencing a surge in "new quality productivity" focused on hard technology and future industries, with R&D investment nearly doubling during the 14th Five-Year Plan period, reaching 210.3 billion yuan in 2024, a 91.35% increase from 2020 [1] - In the first three quarters of 2025, disclosed R&D expenses totaled 156.33 billion yuan, marking a historical high with a year-on-year growth of 11.59%, significantly outpacing the national average [1] - Approximately 80% of newly listed companies are from the Sci-Tech Innovation Board and the Growth Enterprise Market, with a total of 216 companies, representing over half of A-share Shenzhen enterprises, leading among major cities in China [1] Group 2 - A notable "innovation matrix" has formed in Shenzhen, with companies like UBTECH Robotics, Youjia Innovation, and SUTENG Juchuang leading in future industry directions, showcasing Shenzhen's advantages in the new technological revolution and industrial transformation [2] - The "Robot Valley" in Nanshan, centered around companies like UBTECH and Huichuan Technology, has created an industrial ecosystem, with UBTECH's Walker S1 robot being utilized in factories of major companies like BYD and Geely [2] - Huichuan Technology, valued at nearly 200 billion yuan, has increased its R&D investment from 1.023 billion yuan to 3.147 billion yuan over the past five years, successfully developing key components for humanoid robots [2] Group 3 - Innovation is not limited to individual companies but is also evident in collaborative evolution across industries, exemplified by Shenzhen Hanno Medical's breakthrough in developing China's first ECMO system, set to enter the EU market in May 2025 [3] - Mindray Medical, a major shareholder of Hanno Medical, has played a crucial role in supporting its technological advancements, illustrating the model of larger companies fostering innovation in smaller firms within the industry chain [3]

资料显示，京新药业为一家以创新为驱动力的制药集团，重点专注于两大核心疾病领域：中枢神经系统 疾病、心血管及脑血管疾病。 京新药业发展轨迹紧随过去30年中国制药产业的演进，该公司最初专注于中间体与原料药领域，随后将 业务向下游延伸至药物领域。近年来，京新药业开始向创新药方向转型。 京新药业在申请材料中提到，公司既有的商业化业务为创新药物的研发与商业化提供可持续的技术、市 场及财务支持。财务数据方面，2024年，京新药业总收入为41.59亿元，净利为7.19亿元，研发投入约 3.84亿元。京新药业方面表示，公司计划持续维持相当高水平的研发投资，以推进创新战略，并促进成 长。 2月12日早间，京新药业在A股公告，公司已向中国香港联交所递交上市申请，这家最早专注于中间体 与原料药领域，又随着时代发展向创新药转型的老牌药企，正式踏上"A+H"两地上市的旅程。据北京商 报记者不完全统计，今年开年40余日，已有约30家医药企业递表港交所。 药企扎堆赴港，"创新"成为关键词。上述30家企业中，13家为带有特殊标识"B"的未盈利的创新药、创 新医疗器械企业。港交所对未盈利生物科技企业的上市审核，始终锚定产品的创新性、管线的差异 ...

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容 概不負責，對其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問或包銷團成員表示同意： Nanjing Novlead Biotechnology Co., Ltd. 南京諾令生物科技股份有限公司 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，本公 司不會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請 僅依據於香港公司註冊處處長註冊的本公司招股章程作出投資決定，招股章程的文本將於發售期內 ...

阿联酋通讯社（WAM）2月9日消息，沙迦工商会（SCCI）参加于2月4日至5日在阿曼苏哈尔举行 的2026年苏哈尔投资论坛。论坛吸引了来自32个国家的929名代表，为区域投资与商业合作搭建了平 台。沙迦工商会表示，此次参会旨在提升沙迦在区域和国际经济平台上的影响力，展示其作为外资与战 略合作目的地的竞争优势。论坛期间，沙迦代表团重点考察了食品制造、钢铁与采矿、塑料、回收利 用、医疗器械、铝业及重工业配套等投资机会，并与多国商会、经济官员和企业代表举行双边会谈，推 介沙迦自由区政策、产业激励和基础设施优势，并推动与阿曼及周边市场的产业协同与投资合作。 （原标题：沙迦工商会参加2026年苏哈尔投资论坛） ...

Core Viewpoint - Aidi Te (301580.SZ) is progressing with the construction of its dental industrial park as planned, expected to commence production in the second half of this year, which will significantly enhance the company's overall capacity [1] Group 1 - The construction of the dental industrial park is on schedule and will begin production in the latter half of the year [1] - The company plans to release the new park's capacity in phases, aligning it with market demand and order forecasts to ensure efficient utilization of the new capacity [1] - The strategy aims to match the pace of capacity release with the growth rate of orders, ensuring orderly digestion and effective use of the increased capacity [1]

Core Viewpoint - The company, Aidi Te (301580.SZ), positions itself to serve dental laboratories and oral hospitals/clinics by providing dental materials, equipment, and comprehensive digital solutions, without directly engaging in downstream operations and production [1] Group 1 - The company focuses on technology output and capacity empowerment to deliver full-process digital solutions to downstream partners [1]

该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为24.57。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 该股主要指标及行业内排名如下： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：医疗器械精密组件及产品的 ...

近5日资金流向一览见下表： 证券之星消息，截至2026年2月12日收盘，开立医疗(300633)报收于26.88元，上涨0.3%，换手率0.6%， 成交量2.6万手，成交额6960.7万元。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 2月12日的资金流向数据方面，主力资金净流入183.14万元，占总成交额2.63%，游资资金净流出571.2 万元，占总成交额8.21%，散户资金净流入388.07万元，占总成交额5.58%。 该股主要指标及行业内排名如下： 资金流向名词解释：指通过价格变化反推资 ...